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Efforts in prevention and control of tuberculosis suf-
fer from the lack of detailed knowledge of the mecha-
nisms used by pathogenic mycobacteria for survival
within host cell macrophages. The exploitation of host
cell signaling pathways to the benefit of the pathogen is
a phenomenon that deserves to be looked into in detail.
We have tested the hypothesis that lipoarabinomannan
(LAM) from the virulent species of Mycobacterium tuber-
culosis possesses the ability to modulate signaling path-
ways linked to cell survival. The Bcl-2 family member
Bad is a proapoptotic protein. Phosphorylation of Bad
promotes cell survival in many cell types. We demon-
strate that man-LAM stimulates Bad phosphorylation in
a phosphatidylinositol 3-kinase (PI-3K)-dependent path-
way in THP-1 cells. Man-LAM activated PI-3K. LAM-
stimulated phosphorylation of Bad was abrogated in
cells transfected with a dominant-negative mutant of
PI-3K (Dp85), indicating that activation of PI-3K is suf-
ficient to trigger phosphorylation of Bad by LAM. Since
phosphorylation of Bad occurred at serine 136, the tar-
get of the serine/threonine kinase Akt, the effect of LAM
on Akt kinase activity was tested. Man-LAM could acti-
vate Akt as evidenced from phosphorylation of Akt at
Thr308 and by the phosphorylation of the exogenous sub-
strate histone 2B. Akt activation was abrogated in cells
transfected with Dp85. The phosphorylation of Bad by
man-LAM was abrogated in cells transfected with a ki-
nase-dead mutant of Akt. These results establish that
LAM-mediated Bad phosphorylation occurs in a PI-3K/
Akt-dependent manner. It is therefore the first demon-
stration of the ability of a mycobacterial virulence fac-
tor to up-regulate a signaling pathway involved in cell
survival. This is likely to be one of a number of viru-
lence-associated mechanisms by which bacilli control
host cell apoptosis.
Despite the potential role of the macrophage in the eradica-
tion of microbes, pathogenic Mycobacterium species have sur-
vived down the ages as some of the most successful in evading
macrophage surveillance mechanisms in a manner that en-
sures their survival and replication inside the macrophage. A
variety of mechanisms contribute to the survival of Mycobac-
terium tuberculosis within macrophages (1) including inhibi-
tion of phagosome-lysosome fusion (2), inhibition of the acidi-
fication of phagosomes (3), and resistance to killing by reactive
oxygen (4) and reactive nitrogen intermediates (5, 6). M. tuber-
culosis produces large quantities of lipoarabinomannan
(LAM).1 LAM can inhibit macrophage activation and triggering
and represents a virulence factor contributing to the persist-
ence of mycobacteria within macrophages. LAM is a complex
molecule consisting of a phosphatidylinositol (PI) moiety that
anchors a large mannose core to the mycobacterial cell wall
(7–9). The mannose core consists of multiple branched, ar-
abinofuranosyl side chains. M. tuberculosis and M. leprae mod-
ify the nonreducing end of the arabinofuranosyl chains with
mannose residues yielding man-LAM, whereas rapidly growing
mycobacterial species have nonreducing termini of two types,
the linear Ara4 and the branched Ara6 motifs, thereby giving
rise to ara-LAM (7, 10). LAM exhibits a wide array of immu-
nomodulatory functions including inhibition of interferon-g-
induced functions such as macrophage microbicidal and tu-
moricidal activity (11), scavenging of potentially cytotoxic
oxygen free radicals (12), inhibition of protein kinase C activity
(13), and evocation of a number of cytokines such as tumor
necrosis factor-a (14). The early response genes c-fos, KC, and
JE are induced by ara-LAM but not by man-LAM (15). The
ability of man-LAM to impair responsiveness to interferon-g
and to attenuate tumor necrosis factor-a and interleukin-12
mRNA production through effects on the protein phosphatase
SHP-1 has been suggested to be a major mechanism by which
man-LAM promotes intracellular survival (16).
Despite the recent advances, the intracellular signaling fol-
lowing interaction of the mycobacterium with host cells and the
role of LAM in these processes is incompletely understood. The
survival of M. tuberculosis in macrophages probably involves
more than one mechanism. In this study, we have tested
whether LAM plays a role in triggering a signaling pathway
that suppresses the intrinsic cell death machinery of phago-
cytic cells.
The regulation of programmed cell death, apoptosis, is an
exceptionally complicated process that involves a myriad of
proteins. The family of proteins that includes Bcl-2 comprises
members that are both antiapoptotic and those that are pro-
apoptotic such as Bax and Bad. Bad interacts with Bcl-2 and
Bcl-XL, sequestering these proteins, and thus promotes apo-
ptosis (17). Phosphorylation of Bad at either of two sites, serine
residues 112 and 136 (numbering based on the sequence of
murine Bad) creates consensus sites for interaction with the
14-3-3 protein. Bad is then bound to 14-3-3 instead of Bcl-2 or
Bcl-XL, resulting in the liberation of the antiapoptotic proteins
and promotion of cell survival. Interleukin-3 (18) and other
survival factors promote cell survival through their ability to
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stimulate phosphatidylinositol 3-kinase (PI-3K) (19) and inac-
tivate the apoptotic factor Bad (20, 21). The PI-3K-sensitive
pathway involves the activation of the serine/threonine kinase
Akt or protein kinase B (22–25) and direct phosphorylation of
Bad at serine 136 (26–29). Akt/protein kinase B is the major
downstream target of receptor tyrosine kinases that signal via
the PI-3K. Activated protein kinase B has been implicated in
glucose metabolism, transcriptional control, and the regulation
of apoptosis in many cell types (30, 31). In addition to Bad, Akt
also phosphorylates caspase 9 (32), forkhead transcription fac-
tor (33, 34), and the IkB kinase, thereby activating NF-kB
(35, 36).
In addition to phosphorylation at serine 136 mediated by
protein kinase B, Bad undergoes protein kinase A- (37) and
p90RSK- (38) mediated phosphorylation on serine 112. The
Ca21-activated protein phosphatase calcineurin can dephos-
phorylate Bad, reversing the phosphorylation at both serine
112 and serine 136 (39). A third phosphorylation site at serine
155 has recently been identified (40–43). When Bad is bound to
prosurvival Bcl-2 family members, Bad serine 155 phosphoryl-
ation requires the prior phosphorylation at serine 136, which
recruits 14-3-3 proteins that then function to increase the ac-
cessibility of serine 155 to survival-promoting kinases (43). Bad
is not a ubiquitously expressed protein. Nevertheless, several
major signaling pathways influence cell survival through their
effects on the phosphorylation state of Bad (44). We demon-
strate that man-LAM from the virulent Erdman strain of M.
tuberculosis promotes phosphorylation of Bad at serine 136
through a PI-3K/Akt pathway in the human cell line THP-1
and hypothesize that this probably represents one of the mech-
anisms by which man-LAM promotes cell survival to the ben-
efit of the pathogen.
EXPERIMENTAL PROCEDURES
Reagents—-Histone 2B was purchased from Roche Molecular Bio-
chemicals. Phorbol 12-myristate 13-acetate was purchased from Sigma.
Protein A/G Plus-agarose, rabbit anti-p85 phosphoinositide 3-kinase,
goat anti-Akt, and rabbit anti-Bad antibody were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Anti-phophotyrosine antibody
was from Life Technologies, Inc. Wortmannin, LY294002, PD98059,
and SB203580 were from Calbiochem. Phosphorylation state-specific
antibodies Bad (Ser112) and (Ser136) and Akt (Thr308) antibodies and the
Phototope-HRP Chemiluminescent Western Detection Kit were from
New England Biolabs, Inc. (Beverly, MA). All other chemicals were
from Sigma.
Cell Culture and Transfection—THP-1 cells (derived from a patient
with acute monocytic leukemia) are mature cells from the monocyte/
macrophage lineage. These were obtained from the National Center for
Cell Science (Pune, India). Media and supplements were obtained from
Life Technologies, Inc. The cell line was maintained in RPMI 1640
containing 10% heat-inactivated fetal bovine serum, 100 units/ml pen-
icillin, 100 mg/ml streptomycin, 2 mM glutamine, and 20 mM sodium
bicarbonate. The cells were incubated at 5% CO2 and 95% humidity in
a 37 °C chamber. THP-1 cells were treated with phorbol 12-myristate
13-acetate to induce maturation of the monocytes to a macrophage-like,
adherent phenotype. The cells were washed three times with culture
medium without fetal bovine serum and resuspended to a concentration
of 2 3 106 cells/ml. Cell viability was determined to be .95% by the
trypan blue dye exclusion method. 2 3 106 cells were plated in each well
of six-well plates. Cells were deprived of serum by culturing in RPMI
without fetal bovine serum for 12–16 h, before treatment with LAM.
Transfections were carried out on adherent THP-1 cells (2 3 106 cells/
well in six-well plates). Cells were transfected with 2 mg of plasmid
(recombinants or empty vectors) using the Effectene Reagent (Qiagen)
in RPMI with 10% fetal bovine serum according to the manufacturer’s
instructions. The dominant-negative mutant of p85 was deleted in the
inter-SH2 region of wild type p85a (Dp85), which abolishes binding to
the p110 subunit of PI 3-kinase. The kinase-deficient mutant of Akt
(Akt.KD) carried the mutation K179M.
Mycobacterial Lipids—Endotoxin-free man-LAM and ara-LAM were
kindly provided by Dr. John Belisle (Colorado State University, Ft.
Collins, CO, through NIAID, National Institutes of Health, Contract
NO1-AI-75320). Man-LAM was derived from the virulent Erdman
strain of M. tuberculosis. LAM was dissolved at a concentration of 1
mg/ml in pyrogen-free water and diluted with medium before each
experiment.
Immunocomplex Akt Kinase Assay—To assay for Akt protein kinase
activity, cells were lysed in lysis buffer (45); lysates were incubated with
anti-Akt antibody, and kinase assays were carried out with the immu-
noprecipitates using histone 2B as substrate (45). After incubation at
room temperature for 30 min, the reaction was stopped by adding
protein gel denaturing buffer, and the mixture was separated by SDS-
polyacrylamide gel electrophoresis, followed by autoradiography.
Immunocomplex PI 3-kinase Assay—Following immunoprecipitation
of cell lysates with anti-p85 PI-3K antibody, immunoprecipitates were
washed, and PI-3K assays were performed (46). Reactions were carried
out for 15 min at room temperature, phosphorylated lipid products were
extracted and separated on TLC plates (47), and incorporated radioac-
tivity was measured by liquid scintillation counting.
Preparation of Cell Membranes—Cells after treatment without or
with LAM were washed, resuspended in buffer A (137 mM NaCl, 2.7 mM
KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 2.5 mM EDTA, 1 mM EDTA, 1
mM dithiothreitol, and 0.1 mM pefabloc), sonicated twice for 10 s each,
and centrifuged for 5 min at 800 3 g. After discarding the nuclei and
unbroken cells, membranes were prepared by ultracentrifugation at
250,000 3 g for 60 min. The pellets (membranes) were washed and
suspended in buffer A.
Immunoblotting—Cell lysates were prepared as described above and
immunoprecipitated using anti-Akt, anti-Bad, or the respective phos-
phospecific antibodies. The immunoprecipitates were fractionated on
SDS-polyacrylamide (10% for Akt and 12% for Bad) gels and trans-
ferred to nitrocellulose membranes. Membranes were blocked with 5%
nonfat dry milk, incubated with primary antibody overnight at 4 °C,
followed by goat anti-rabbit secondary antibody conjugated to horserad-
ish peroxidase for 1 h at room temperature, and finally visualized using
the Phototope-HRP Western detection kit.
RESULTS
Phosphorylation of Bad—Following treatment of THP-1 cells
with man-LAM, the phosphorylation status of Bad was exam-
ined using phosphospecific antibodies. Man-LAM from the vir-
ulent Erdman species of M. tuberculosis promoted the phospho-
rylation of Bad at Ser136 in a time-dependent manner (Fig. 1A).
LAM from a fast growing species (ara-LAM) did not exhibit an
effect equivalent to that of man-LAM (data not shown). Phos-
FIG. 1. Man-LAM-induced phosphorylation of Bad in THP-1
cells. Differentiated THP-1 cells in serum-free medium were incubated
with man-LAM (2 mg/ml) for different periods of time, followed by
immunoprecipitation of lysates with anti-Bad antibody, SDS-polyacryl-
amide gel electrophoresis, and immunoblotting and development by
enhanced chemiluminescence as described under “Experimental Proce-
dures.” A, a representative Western blot using anti-phospho-Bad Ser136.
Total Bad was immunoblotted to confirm equal loading. B, cells were
treated with either wortmannin (lanes e, f, and g, representing concen-
trations of 1.5, 15, and 150 nM, respectively) for 45 min or LY294002
(lanes h, i, and j, representing concentrations of 2, 20, and 200 mM,
respectively) for 4 h or vehicle (DMSO) (lanes a and c, representing
treatment for 45 min, and lanes b and d, representing treatment for 4 h,
respectively). Cells were then either not treated (lanes a and b) or
treated (lanes c–j) with 2 mg/ml man-LAM for 60 min. Bad phosphoryl-
ation was then visualized using phospho-Bad antibodies after lysing the
cells. Total Bad was immunoblotted to confirm equal loading.
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phorylation of Bad at serine 112 was not observed.
PI-3K Inhibitors Block Bad Phosphorylation—The phospho-
rylation of Bad at serine 136 occurs through a PI-3K/Akt-de-
pendent pathway (26–29). Cells were pretreated with selective
inhibitors prior to stimulation with man-LAM in order to test
their ability to block Bad phosphorylation. The PI-3K inhibi-
tors wortmannin and LY294002 inhibited Bad phosphorylation
at serine 136 in a dose-dependent manner (Fig. 1B). The
MEKK1 inhibitors PD90859 and SB20358 did not influence
Bad phosphorylation (data not shown). It was inferred that
man-LAM signals through PI-3K to phosphorylate Bad.
LAM Activates PI-3K—Since man-LAM-induced Bad phos-
phorylation was abrogated by PI-3K inhibitors, in vitro PI-3K
activity was tested after treatment with man-LAM. Man-LAM
was found to stimulate PI-3K activity (Fig. 2A) in a time-de-
pendent manner. Control experiments showed that equal
amounts of precipitated PI-3K were used to assay kinase
activity.
Activation of heterodimeric (p85-p110) PI-3K is often pro-
moted by recruitment to the plasma membrane through inter-
action of SH2 domains in p85 with tyrosine-phosphorylated
proteins. Treatment with man-LAM caused a time-dependent
increase in the amount of the p85 subunit detected in the
membrane fraction, indicating translocation from the cytosol
(Fig. 2B). Tyrosine phosphorylation of p85 might represent
another mechanism of PI-3K activation (48). Cell lysates were
immunoprecipitated with anti-p85 and analyzed by Western
blotting with anti-phosphotyrosine antibody. man-LAM treat-
ment increased the tyrosine phosphorylation of the p85a sub-
unit of PI-3K in a time-dependent manner (Fig. 2C).
Akt Activation by LAM—The PI-3K-sensitive pathway of Bad
phosphorylation involves the activation of the protein kinase
Akt (or protein kinase B) and the phosphorylation of Bad at
serine 136. The interaction of the amino-terminal pleckstrin
homology domain of Akt with the phospholipid product of
PI-3K induces a conformational change in Akt, making it a
more efficient substrate for the phosphatidylinositide-depend-
ent kinase 1 (49–51). Stimulus-induced Akt phosphorylation
on Thr308 by phosphatidylinositide-dependent kinase 1 and on
Ser473 is required for maximal activity. To determine whether
Akt is a downstream effector of man-LAM-induced PI-3K sig-
naling in THP-1 cells, Akt phosphorylation on Thr308 was
measured using immunoblotting with phosphospecific Thr308
anti-Akt antibody, followed by densitometric analysis of the
autoradiograms. Man-LAM-stimulated phosphorylation of Akt
at Thr308 in a dose-dependent (Fig. 3A) and time-dependent
(Fig. 3B) manner.
Stimulation of Akt Kinase Activity by Man-LAM—LAM stim-
ulated histone 2B phosphorylation in a time-dependent man-
ner (Fig. 3C), indicating LAM-induced stimulation of Akt ki-
nase activity. Histone phosphorylation stimulated by man-
LAM was inhibited by the PI-3K inhibitors wortmannin and
LY294002 (Fig. 3D). Unlike man-LAM, exposure of cells to
ara-LAM for 60 min did not result in stimulation of Akt kinase
activity (Fig. 3D, lanes g–i).
Expression of a Dominant Negative Mutant of p85a Abolishes
Akt Kinase Activation—To establish whether Akt is the serine/
threonine kinase that is downstream of PI-3K in the man-LAM
signaling pathway, the effect of expression of the dominant
negative mutant of p85a on LAM-induced Akt kinase activa-
tion was assessed. Thr308 phosphorylation of Akt was abro-
gated by expression of the Dp85 mutant of PI-3K but not by the
control empty vector (Fig. 3E). In harmony with this, Bad
phosphorylation at serine 136 was also abrogated in cells ex-
pressing Dp85 (data not shown).
Kinase-deficient Akt Mutant (Akt.KD) Blocks Man-LAM-in-
duced Phosphorylation of Bad—In order to establish a connec-
tion between Akt kinase activation and the phosphorylation of
Bad at serine 136 induced by LAM, we transfected THP-1 cells
with a kinase-dead mutant (K179M) of Akt and assessed the
phosphorylation status of Bad. Akt.KD abrogated the phospho-
rylation of Bad following stimulation by LAM, whereas control
empty vector had no such effect (Fig. 3F).
FIG. 2. Man-LAM-induced activation of PI 3-kinase in THP-1 cells. A, serum-starved cells were exposed to man-LAM(2 mg/ml) for different
time periods followed by immunoprecipitation of lysates with anti-p85 PI 3-kinase antibody. PI 3-kinase activity was assayed using PI as substrate
as described under “Experimental Procedures,” and PIP was detected by autoradiography after separation by TLC (top panel). The middle panel
represents a densitometric analysis of the autoradiograms. Data represent the mean 6 S.E. of three independent experiments. The bottom panel
is a Western blot of anti-p85 in the immunoprecipitate. Lanes a, b, c, d, and e represent the time points 0, 5, 10, 30, and 60 min, respectively. B,
translocation of PI-3K to the membrane. The top panel shows the effect of man-LAM (2 mg/ml) treatment for different time periods on the
translocation of p85a to the membrane fraction as measured by Western blotting using anti-p85a antibody. Lanes a, b, c, and d represent time
points 0, 10, 30, and 60 min, respectively. The bottom panel is a densitometric analysis of the blot. Error bars illustrate S.E. from three independent
experiments. C, tyrosine phosphorylation of PI-3K by LAM. Cells after treatment were lysed and immunoprecipitated with anti-p85a, followed by
immunoblotting with anti-phosphotyrosine antibody as described under “Experimental Procedures.” The top panel shows the effect of man-LAM
(2 mg/ml) treatment for different time periods on the tyrosine phosphorylation of p85a. The bottom panel is a representative Western blot of
anti-p85a to show that the same amount of p85a was present in each sample. Lanes a, b, c, and d represent the time points 0, 10, 30, and 60 min.
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DISCUSSION
The molecular basis of the pathogenicity of M. tuberculosis is
poorly understood. M. tuberculosis is a facultative intracellular
pathogen. Whereas the normal function of macrophages is to
engulf and destroy microorganisms, mycobacteria have evolved
ways to circumvent the defense mechanisms of macrophages.
Central to the ability of M. tuberculosis to infect the host and
cause active or latent disease is the propensity of the tubercle
bacillus to enter the host mononuclear phagocyte and survive
and multiply within macrophages. Macrophage apoptosis con-
tributes to host defense against M. tuberculosis infection. Hu-
man alveolar macrophages undergo apoptosis in response to M.
tuberculosis infection (52). Very recently it has been demon-
strated that bacillary control of host cell apoptosis is a viru-
lence-associated phenotype of M. tuberculosis, with virulent
strains having the ability to evade apoptosis of infected macro-
phages (53). In light of these observations, understanding the
virulence factors that may modulate host cell apoptosis is nec-
essary. We chose to study whether man-LAM from a virulent
strain of M. tuberculosis could modulate cell signaling path-
ways known to control cell survival.
The phosphorylation of Bad is one of the mechanisms of
protection of cells from programmed cell death. We have tested
the hypothesis that man-LAM from the virulent species of M.
tuberculosis protects cells from apoptosis at least partly
through phosphorylation of Bad. Man-LAM was found to stim-
ulate Bad phosphorylation on serine 136 in THP-1 cells. Bad
phosphorylation at serine 136 is believed to occur via a PI-3K/
Akt signaling pathway. Consistent with this, the PI-3K inhib-
itors wortmannin and LY294002 inhibited the LAM-stimulated
phosphorylation of Bad. Activation of PI-3K was observed after
stimulation of cells with LAM. Furthermore, LAM caused p85
to translocate to the membrane, a phenomenon associated with
enhanced lipid kinase activity of this enzyme. Tyrosine phos-
phorylation of p85 may represent another mechanism of PI-3K
activation. LAM stimulated tyrosine phosphorylation of p85.
The fact that PI-3K activation is sufficient for Bad phosphoryl-
ation upon treatment of cells with LAM was demonstrated by
the fact that transfection of THP-1 cells with the dominant
negative mutant (Dp85) of PI-3K abrogated LAM-mediated Bad
phosphorylation. One of the major functions of Akt is protection
of cells from programmed cell death. This protection has been
demonstrated for several cell types including COS cells (23),
fibroblasts (24), and neuronal cells (55). This is at least in part
due to the ability of Akt to phosphorylate Bad at serine 136. We
attempted to establish a connection between PI-3K, Akt, and
the phosphorylation of Bad. Akt phosphorylation at Thr308 was
stimulated by LAM in a PI-3K-sensitive manner. Akt kinase
activity assessed by using histone 2B as exogenous substrate
was also stimulated by LAM. Transfection of THP-1 with the
FIG. 3. Effect of man-LAM on Akt and Bad phosphorylation. A, serum-starved cells were exposed to man-LAM at different concentrations
for 30 min. Lysates were immunoprecipitated with anti-Akt antibody followed by immunoprecipitation with phospho-Akt Thr308 antibody.
Immunoprecipitates were separated on SDS-polyacrylamide gels, followed by Western blotting with phospho-Akt Thr308, development by enhanced
chemiluminescence, and densitometric analysis (top panel). Data represent the mean 6 S.E. of three independent experiments. The bottom panel
is a representative Western blot showing that equal amounts of immunoprecipitated Akt protein were detected by immunoblotting in each sample.
B, cells were exposed to man-LAM for different time periods. Lysates were immunoprecipitated with anti-Akt antibody followed by Western
blotting with control Akt or phospho-Akt Thr308. The bottom panel is a densitometric analysis of the autoradiograms. Error bars represent S.E. of
three independent determinations. C, cells were treated with man-LAM for different time periods, and Akt kinase activity was measured following
immunoprecipitation with anti-Akt antibody using histone 2B as substrate (top panel). The bottom panel shows the amount of immunoprecipitated
Akt protein in each sample. D, cells were treated with either 100 nM wortmannin (lane c) for 45 min or 50 mM LY294002 (lane f) for 4 h or vehicle
(DMSO) (lanes a and b representing treatment for 45 min and lanes d and e representing treatment for 4 h, respectively). Cells were then either
not treated (lanes a and d) or treated (lanes b, c, e, and f) with 2 mg/ml man-LAM for 60 min. Cells were treated either with medium (lane g) or
with 2 mg/ml man-LAM (lane h) or with 2 mg/ml ara-LAM (lane i) for 60 min. Akt kinase activity was measured using histone 2B as substrate. E,
cells were transfected with a dominant negative mutant of p85a (lanes c and d) or the control empty vector (lanes a and b) using Effectene as
described. After transfection, cells were serum-starved and stimulated without (lanes a and c) or with (lanes b and d) man-LAM (2 mg/ml) for 60
min. Akt phosphorylation was then visualized (lower blot) after lysing the cells. The upper blot shows that the same amount of Akt protein was
present in each sample. F, cells were transfected with a kinase-deficient mutant of Akt (Akt.KD) (lanes c and d) or with control empty vector (lanes
a and b). After transfection, cells were serum-starved and stimulated without (lanes a and c) or with (lanes b and d) man-LAM (2 mg/ml) for 60 min.
Bad phosphorylation was then visualized (lower blot) after lysing the cells. The upper blot shows that the same amount of Bad protein was present
in each sample.
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Dp85a mutant of PI-3K abolished the LAM-stimulated phos-
phorylation of Akt at Thr308 as well as the ability of Akt to
phosphorylate histone 2B, establishing that Akt is a down-
stream effector of LAM-mediated PI-3K signaling. The connec-
tion between Akt and Bad was similarly established by trans-
fecting cells with a kinase-deficient mutant of Akt (Akt.KD)
and assessing the phosphorylation of Bad after stimulation
with LAM. LAM-mediated Bad phosphorylation was abolished
in cells transfected with Akt.KD. In summary, we demonstrate
that man-LAM from the virulent Erdman strain of M. tuber-
culosis activates Akt in a PI-3K-sensitive manner, leading to
the phosphorylation of Bad at serine 136, suggesting that this
may be one of the mechanisms by which LAM directly promotes
macrophage cell survival. Inhibition of macrophage apoptosis
would allow the mycobacteria to escape from being packaged
into apoptotic bodies. Uptake of bacilli packaged in this way is
suggested to result in more effective microbicidal processing
(54).
This is the first demonstration of a mycobacterial virulence
factor having the capability of up-regulating a macrophage
survival signaling pathway, thereby creating an environment
favorable for the survival of the pathogen.
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